Pfizer considers sale of Consumer Healthcare business

Pfizer organises company into three businesses
Credit: Rob Wilson

Pfizer is pontificating about the future of its Consumer Healthcare business as the pharma giant mulls over sale and spin-out options.

The company said that a “range of options” will be considered and go from a full or partial separation via a spin-off, sale or other transaction.

Pfizer added that it might yet decide to retain the business.

Pfizer Consumer Healthcare is one of the largest OTC health care products businesses in the world with 2016 revenues of approximately $3.4 billion, operating in more than 90 countries globally.

Consumer Healthcare markets two of the ten top selling consumer healthcare brands globally – Centrum and Advil.

In addition, the business has ten brands that each exceeded $100 million in 2016 sales, and several local brands that are top-ranked in their respective markets.

It develops, manufactures and markets leading non-prescription medicines, vitamins, and personal care products.